NCT03106623 - Study of ONO-8577 in Patients With Overactive Bladder | Biotech Hunter

Enrollment

207

Participants

Timeline

Start Date

April 7, 2017

Primary Completion Date

August 29, 2017

Study Completion Date

September 26, 2017

Conditions

Overactive Bladder

Interventions

DRUG

ONO-8577

Oral administration of ONO-8577 once a daily for 4 weeks

DRUG

solifenacin succinate + mirabegron

Oral administration of solifenacin succinate and mirabegron once a daily for 4 weeks

DRUG

Placebo

Oral administration of Placebo once a daily for 4 weeks

Trial Locations (30)

Unknown

Gunma Clinical Site 02, Maebashi

Gunma Clinical Site 01, Takasaki

Hyogo Clinical Site 02, Akashi

Hyogo Clinical Site 01, Kobe

Hyogo Clinical Site 03, Kobe

Hyogo Clinical Site 04, Takarazuka

Kanagawa Clinical Site 01, Isehara

Kanagawa Clinical Site 02, Kamakura

Kanagawa Clinical Site 03, Sagamihara

Kanagawa Clinical Site 04, Yokohama

Osaka Clinical Site 03, Higashiosaka

Osaka Clinical Site 04, Ibaraki

Osaka Clinical Site 02, Osaka

Osaka Clinical Site 05, Suita

Osaka Clinical Site 06, Toyonaka

Osaka Clinical Site 07, Toyonaka

Saitama Clinical Site 01, Kumagaya

Osaka Clinical Site 01, Osaka

Tokyo Clinical Site 10, Bunkyo-ku

Tokyo Clinical Site 01, Edogawa-ku

Tokyo Clinical Site 06, Itabashi-ku

Tokyo Clinical Site 09, Nakano-ku

Tokyo Clinical Site 07, Nerima-ku

Tokyo Clinical Site 03, Ōta-ku

Tokyo Clinical Site 08, Setagaya-ku

Tokyo Clinical Site 11, Setagaya-ku

Tokyo Clinical Site 04, Shinagawa-ku

Tokyo Clinical Site 05, Shinagawa-ku

Tokyo Clinical Site 02, Suginami-ku

Kyoto Clinical Site 01, Kyoto